# PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC

> **NCT04284202** · PHASE2 · UNKNOWN · sponsor: **The Affiliated Hospital of Qingdao University** · enrollment: 30 (estimated)

## Conditions studied

- NSCLC Stage IV
- ARID1A
- PD-1

## Interventions

- **DRUG:** PD-1 plus Dasatinib

## Key facts

- **NCT ID:** NCT04284202
- **Lead sponsor:** The Affiliated Hospital of Qingdao University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04284202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04284202, "PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04284202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*